Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.

Epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) are potent mitogens that regulate proliferation of prostate cancer cells via autocrine and paracrine loops and promote tumor metastasis. They exert their action through binding to the corresponding cell surface receptors that initiate an intracellular phosphorylation cascade, leading to the activation of mitogen-activated protein kinases (MAPKs), which recruit transcription factors. We have studied the effects of EGF, IGF-I, and the protein kinase A (PKA) activator forskolin on the activation of p42/ extracellular signal-regulated kinase (ERK)2, which is a key kinase in mediation of growth factor-induced mitogenesis in prostate cancer cells. The activity of p42/ERK2 was determined by immune complex kinase assays and by immunoblotting using a phospho p44/p42 MAPK-specific antibody. EGF, IGF-I, and forskolin-induced PKA activity stimulate intracellular signaling pathways converging at the level of p42/ERK2. In the androgen-insensitive DU145 cell line, there is a constitutive basal p42/ ERK2 activity that is not present in androgen-sensitive LNCaP cells. Constitutive p42/ERK2 activity is abrogated by blockade of the EGF receptor. Hence, it is obviously caused by an autocrine loop involving this receptor. The effects of EGF on p42/ERK2 are potentiated by forskolin in both cell lines. The blockade of PKA by the specific inhibitor H89 attenuates this synergism. This finding is in contrast to those obtained in several other systems studied thus far, in which PKA activators inhibited MAPKs. p42/ERK2 in DU145 cells is highly responsive to IGF-I stimulation, whereas no effect of IGF-I on p42/ERK2 can be measured in LNCaP cells. Moreover, our results demonstrate that selective blockade of the EGF receptor in prostate cancer cells does not only inhibit the action of EGF, but also IGF-I-induced activation of the MAPK pathway and the interaction with the PKA pathway. In conclusion, these findings offer new possibilities for a therapeutical intervention in prostate cancer by targeting signaling pathways of growth factors and PKA.

[1]  J. Lawrence,et al.  Increasing cAMP attenuates activation of mitogen-activated protein kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[3]  W. Rayford,et al.  Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients. , 1994, Endocrinology.

[4]  S. Mohan,et al.  Insulin‐Like Growth Factor (IGF) System Components in Human Prostatic Cancer Cell‐Lines: LNCaP, DU145, and PC‐3 Cells , 1996, International journal of urology : official journal of the Japanese Urological Association.

[5]  D. Rose,et al.  Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line , 1989, The Prostate.

[6]  X. Zhu,et al.  Steroid-independent activation of androgen receptor in androgen-independent prostate cancer A possible role for the MAP kinase signal transduction pathway? , 1997, Molecular and Cellular Endocrinology.

[7]  J. Dodd,et al.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. , 1990, The Journal of urology.

[8]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[9]  P. Hordijk,et al.  cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. , 1994, The Journal of biological chemistry.

[10]  R. Agarwal,et al.  A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. , 1998, Cancer research.

[11]  D. Rose,et al.  Regulation of DUI45 human prostate cancer cell proliferation by insulin‐like growth factors and its interaction with the epidermal growth factor autocrine loop , 1994, The Prostate.

[12]  G. Tortora,et al.  Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  B. Ursø,et al.  The Insulin-Like Growth Factor-I Receptor , 1994, Hormone Research.

[14]  D. Rose,et al.  Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor‐related polypeptides , 1991, The Prostate.

[15]  H. Scher,et al.  Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. , 1996, Cancer research.

[16]  D. Samid,et al.  Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. , 1996, Molecular pharmacology.

[17]  M. Gleave,et al.  Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. , 1991, Cancer research.

[18]  D T Denhardt,et al.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. , 1996, The Biochemical journal.

[19]  R. Baserga,et al.  Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[20]  J. Veldscholte,et al.  Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  P. Worley,et al.  Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals , 1997, Molecular and cellular biology.

[22]  D. Rose,et al.  Endogenous secretion of epidermal growth factor peptides stimulates growth of DU145 prostate cancer cells. , 1991, Cancer letters.

[23]  R. Medema,et al.  Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways , 1993, Molecular and cellular biology.

[24]  R. Davis,et al.  MAPKs: new JNK expands the group. , 1994, Trends in biochemical sciences.

[25]  O. Seternes,et al.  Synergistic increase in c-fos expression by simultaneous activation of the ras/raf/map kinase- and protein kinase A signaling pathways is mediated by the c-fos AP-1 and SRE sites. , 1998, Biochimica et biophysica acta.

[26]  G. Cooper,et al.  Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells , 1995, Molecular and cellular biology.

[27]  D. Neal,et al.  Peptide growth factors in the prostate as mediators of stromal epithelial interaction. , 1996, British journal of urology.

[28]  I. Fidler,et al.  Metastatic behavior of human tumor cell lines grown in the nude mouse. , 1984, Cancer research.

[29]  Norepinephrine stimulates mitogen-activated protein kinase activity in GT1-1 gonadotropin-releasing hormone neuronal cell lines. , 1997, Endocrinology.

[30]  S. Cook,et al.  Inhibition by cAMP of Ras-dependent activation of Raf. , 1993, Science.

[31]  S. Brüsselbach,et al.  Abrogation of c-Raf expression induces apoptosis in tumor cells , 1998, Oncogene.

[32]  F. Habib,et al.  Production and response of a human prostatic cancer line to transforming growth factor-like molecules. , 1990, British Journal of Cancer.

[33]  W. Kolch,et al.  Mechanism of inhibition of Raf-1 by protein kinase A , 1994, Molecular and cellular biology.

[34]  H. Bourne,et al.  Differential effects on cAMP on the MAP kinase cascade: evidence for a cAMP-insensitive step that can bypass Raf-1. , 1995, Molecular biology of the cell.

[35]  A. Schuurmans,et al.  Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP , 1988, The Prostate.

[36]  D. Rose,et al.  Production of epidermal growth factor and transforming growth factor‐α by the androgen‐responsive LNCaP human prostate cancer cell line , 1990, The Prostate.

[37]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[38]  E. Van Obberghen,et al.  Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. , 1994, The Journal of biological chemistry.

[39]  P. Pelicci,et al.  The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor , 1997, Oncogene.

[40]  J. Ortonne,et al.  Mitogen-activated Protein Kinase Pathway and AP-1 Are Activated during cAMP-induced Melanogenesis in B-16 Melanoma Cells (*) , 1995, The Journal of Biological Chemistry.

[41]  D. Tindall,et al.  The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. , 1997, Endocrinology.

[42]  H. Klocker,et al.  Regulation of prostatic growth and function by peptide growth factors , 1996, The Prostate.

[43]  M. Motta,et al.  Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  P. Sluss,et al.  Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.

[45]  H. Klocker,et al.  Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? , 1997, Histology and histopathology.

[46]  W. Rosner,et al.  Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. , 1996, Endocrinology.

[47]  E. Van Obberghen,et al.  The Effect of Cyclic Adenosine Monophosphate on the Mitogen-Activated Protein Kinase Pathway Depends on Both the Cell Type and the Type of Tyrosine Kinase-Receptor. , 1997, Endocrinology.

[48]  P. Dent,et al.  Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. , 1993, Science.

[49]  J. Rhim,et al.  ErbB kinases and NDF signaling in human prostate cancer cells , 1997, Oncogene.

[50]  I. Takenaka,et al.  Role of cyclic AMP and polypeptide growth regulators in growth inhibition by interferon in PC‐3 cells , 1991, The Prostate.

[51]  A. MacDonald,et al.  Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. , 1992, British Journal of Cancer.

[52]  D. Yee,et al.  Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. , 1995, The Journal of clinical endocrinology and metabolism.

[53]  E. Krebs,et al.  Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  C. Wood,et al.  Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. , 1998, British Journal of Cancer.

[55]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[56]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[57]  J. Mendelsohn,et al.  Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. , 1992, Cancer research.

[58]  J. Scott.  Cyclic nucleotide-dependent protein kinases. , 1991, Pharmacology & therapeutics.